05/13/2026 | Press release | Distributed by Public on 05/13/2026 15:19
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
Initial public offering price(1)
|
|
|
Underwriting discount
|
|
|
Proceeds, before expenses, to
the Issuer
|
||||||||||
|
|
|
Per Note
|
|
|
Total
|
|
|
Per Note
|
|
|
Total
|
|
|
Per Note
|
|
|
Total
|
|
|
Note
|
|
|
100.000%
|
|
|
€600,000,000
|
|
|
0.400%
|
|
|
€2,400,000
|
|
|
99.600%
|
|
|
€597,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Plus accrued interest from May 20, 2026, if settlement occurs after that date.
|
|
|
|
|
|
|
|
|
|
|
|
|
Barclays
|
|
|
BNP PARIBAS
|
|
|
Goldman Sachs & Co. LLC
|
|
|
Morgan Stanley
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MUFG
|
|
|
Scotiabank
|
|
|
US Bancorp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Academy Securities
|
|
|
Santander
|
|
|
ING
|
|
|
IMI - Intesa Sanpaolo
|
|
|
|
|
|
|
|
||||
|
Loop Capital Markets
|
|
|
Siebert Williams Shank
|
|
|
Standard Chartered Bank
|
|
|
TD Securities
|
|
|
|
|
|
|
|
|
|
|
|
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
Page
|
|
|
ABOUT THIS PROSPECTUS SUPPLEMENT
|
|
|
S-ii
|
|
STABILIZATION
|
|
|
S-ii
|
|
WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION BY REFERENCE
|
|
|
S-v
|
|
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
|
|
|
S-vi
|
|
SUMMARY
|
|
|
S-1
|
|
RISK FACTORS
|
|
|
S-7
|
|
USE OF PROCEEDS
|
|
|
S-13
|
|
CAPITALIZATION
|
|
|
S-14
|
|
DESCRIPTION OF NOTES
|
|
|
S-16
|
|
BOOK-ENTRY; DELIVERY AND FORM
|
|
|
S-23
|
|
U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR U.S. HOLDERS
|
|
|
S-27
|
|
CERTAIN LUXEMBOURG TAX CONSIDERATIONS
|
|
|
S-31
|
|
UNDERWRITING (CONFLICTS OF INTEREST)
|
|
|
S-34
|
|
LEGAL MATTERS
|
|
|
S-41
|
|
EXPERTS
|
|
|
S-41
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
BECTON, DICKINSON AND COMPANY
|
|
|
1
|
|
BECTON DICKINSON EURO FINANCE S.À R.L.
|
|
|
1
|
|
WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION BY REFERENCE
|
|
|
2
|
|
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
|
|
|
3
|
|
RISK FACTORS
|
|
|
4
|
|
USE OF PROCEEDS
|
|
|
4
|
|
DESCRIPTION OF SECURITIES
|
|
|
4
|
|
DESCRIPTION OF CAPITAL STOCK OF BECTON, DICKINSON AND COMPANY
|
|
|
5
|
|
DESCRIPTION OF DEPOSITARY SHARES OF BECTON, DICKINSON AND COMPANY
|
|
|
8
|
|
DESCRIPTION OF DEBT SECURITIES OF BECTON, DICKINSON AND COMPANY
|
|
|
9
|
|
DESCRIPTION OF WARRANTS OF BECTON, DICKINSON AND COMPANY
|
|
|
15
|
|
DESCRIPTION OF PURCHASE CONTRACTS OF BECTON, DICKINSON AND COMPANY
|
|
|
16
|
|
DESCRIPTION OF UNITS OF BECTON, DICKINSON AND COMPANY
|
|
|
17
|
|
DESCRIPTION OF DEBT SECURITIES OF BECTON DICKINSON EURO FINANCE S.À R.L.
|
|
|
18
|
|
FORMS OF SECURITIES
|
|
|
26
|
|
PLAN OF DISTRIBUTION
|
|
|
28
|
|
VALIDITY OF SECURITIES
|
|
|
30
|
|
EXPERTS
|
|
|
30
|
|
|
|
|
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
(a)
|
corporation (which is not an Accredited Investor), the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an Accredited Investor, or
|
|
(b)
|
trust (where the trustee is not an Accredited Investor), the sole purpose of which is to hold investments and each beneficiary of which is an Accredited Investor, securities or securities-based derivatives contracts (each as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in such trust shall not be transferred within six months after that corporation or trust has subscribed for or acquired the notes except:
|
|
(1)
|
to an Institutional Investor, an Accredited Investor, a Relevant Person or which arises from an offer referred to in Section 275(1A) of the SFA (in the case of that corporation) or Section 276(4)(c) (ii) of the SFA (in the case of that trust);
|
TABLE OF CONTENTS
|
(2)
|
where no consideration is or will be given for the transfer;
|
|
(4)
|
as specified in Regulation 37A of the Securities and Futures (offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.
|
|
(a)
|
BD's Annual Report on Form 10-K for the fiscal year ended September 30, 2025;
|
|
(b)
|
BD's Quarterly Reports on Form 10-Q for the quarters ended December 31, 2025 and March 31, 2026;
|
|
(c)
|
the portions of BD's Definitive Proxy Statement on Schedule 14A for its 2026 annual meeting of stockholders filed with the SEC on December 18, 2025 that are incorporated by reference into its Annual Report on Form 10-K for the fiscal year ended September 30, 2025; and
|
|
(d)
|
BD's Current Reports on Form 8-K filed with the SEC on October 15, 2025 (as amended by the Current Report on Form 8-K/A filed on May 7, 2026), November 17, 2025 (as amended by the Current Report on Form 8-K/A filed on December 1, 2025), January 6, 2026, January 30, 2026, February 5, 2026, February 9, 2026, February 10, 2026, February 25, 2026, April 9, 2026, and April 29, 2026 in each case other than information furnished under Item 2.02 or 7.01 of Form 8-K.
|
TABLE OF CONTENTS
|
•
|
General global, regional or national economic downturns and macroeconomic trends, including heightened inflation, capital market volatility (including volatility resulting from the imposition of (and changing policies around) tariffs and related countermeasures and developments regarding refunds of certain tariffs), import or export licensing requirements, other governmental restrictions, interest rate and currency rate fluctuations, global oil prices and economic slowdown or recession, that may result in unfavorable conditions that could negatively affect demand for our products and services, impact the prices we can charge for our products and services, disrupt aspects of our supply chain, impair our ability to produce our products, or increase borrowing costs.
|
|
•
|
The impact of inflation, tariffs, global oil prices and disruptions in our global supply chain on us and our suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain components, used in the production or sterilization of our products, transportation constraints, disruptions and delays, product shortages, energy shortages or increased energy costs, labor shortages or disputes, and increased operating and labor costs.
|
|
•
|
Conditions in international markets, including social and political conditions, geopolitical developments such as the continuation and/or escalation of the situations in the Iran and Middle East region (which could result in continued disruption of transportation lanes and global energy supplies, as well as increases in global oil prices and adversely affect our supply chain costs, ability to source raw materials and components and our ability to deliver product to customers), Ukraine and Asia, civil unrest, political conflict, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, economic sanctions, export controls, tariffs and other protectionist measures, barriers to market participation (such as local company and products preferences), difficulties in protecting and enforcing our intellectual property rights, and governmental expropriation of assets. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption and bribery laws, as well as regulatory and privacy laws.
|
|
•
|
The impact of changes in U.S. federal, state, or foreign laws and policies that could affect fiscal and tax policies, taxation (including tax reforms such as the Pillar Two framework) and international trade, including import and export licensing regulation and international trade agreements. In particular,
|
TABLE OF CONTENTS
|
•
|
Cost-containment efforts and other measures to improve compliance of healthcare practitioners in the U.S. or in other countries in which we do business, such as alternative payment reform, government-imposed pay back provisions, increased use of competitive bidding and tenders, including, without limitation, any expansion of the volume-based procurement process in China or the Center for Medicaid Services' Competitive Bidding Program, reimbursement policy changes or the implementation of similar cost-containment efforts.
|
|
•
|
The risks associated with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters, including factors that could diminish our benefits from the transaction.
|
|
•
|
Competitive factors that could adversely affect our operations, including new product introductions and technologies, including the use of emerging technologies (such artificial intelligence ("AI")) by our current or future competitors, changes in demand as a result of changes to U.S. federal and state policies (affecting products such as pharmaceuticals and vaccines), change in research and development efforts, investment or suspension by pharmaceuticals companies with regard to vaccine development, consolidation or strategic alliances among healthcare companies, distributors and/or payers of healthcare to improve their competitive position or develop new models for the delivery of healthcare, increased pricing pressure due to the impact of low-cost manufacturers, patents attained by competitors (particularly as patents on our products expire), new entrants into our markets, changes in the practice of medicine or the development of alternative therapies for disease states that may be delivered without a medical device.
|
|
•
|
Product efficacy or safety concerns, changes to, or limitations on, the labeled indications or permitted uses of our products, non-compliance with applicable regulatory requirements regarding our products, including marketing authorization, registration, quality system and manufacturing requirements (including as a result of product modifications); or other factors that could result in product recalls, field actions, lost revenue, restrictions on our ability to continue selling existing products or commercialize new products (including limitations on future product clearances or approvals and the imposition of civil penalties), increased exposure to product liability or other claims and damage to our reputation, including products we acquire through acquisitions. As a result of the CareFusion acquisition, our U.S. infusion pump business is operating under a Consent Decree with the FDA. The Consent Decree authorizes the FDA, in the event of any violations in the future, to order our U.S. infusion pump business to cease manufacturing and distributing products, recall products or take other actions, and order the payment of significant monetary damages if the business subject to the decree fails to comply with any provision of the Consent Decree. In accordance with our commitments to the FDA, the overall timing of replacement of the BD Alaris™ Infusion Systems and return to market in the U.S. may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA.
|
|
•
|
Policy and regulatory changes implemented by the U.S. federal government, including the downsizing and reduced funding of certain government agencies and programs as well as changes in the policy positions of such agencies, including the FDA, may affect the approach of agencies with which we typically engage and make regulatory approval processes and ongoing compliance with all applicable rules and regulations more challenging.
|
TABLE OF CONTENTS
|
•
|
Deficit reduction efforts, policy changes, or other actions that reduce or freeze the availability of government funding for healthcare, which could weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.
|
|
•
|
Changes in the way healthcare services are delivered, including transition of more care from acute to non-acute settings and increased focus on chronic disease management, which may affect the demand for our products and services. Additionally, budget constraints and staffing shortages, particularly shortages of nursing staff, may affect the prioritization of healthcare services, which could also impact the demand for certain of our products and services.
|
|
•
|
Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.
|
|
•
|
Changes in market dynamics, coverage policies or reimbursement practices, or adverse third-party payer cost containment measures relating to our products and services, which could reduce demand for our products or the price we can charge for such products.
|
|
•
|
Changes in the domestic and foreign healthcare industry, in medical or clinical practices or in patient preferences that result in a reduction in procedures using our products or increased pricing pressures, including cost-reduction measures instituted by and the continued consolidation among healthcare providers.
|
|
•
|
The effects of regulatory or other events that adversely impact our supply chain, including our ability to manufacture or sterilize our products (particularly where production of a product line or sterilization operations are concentrated in one or a few plants), source materials or components or services from suppliers (including sole-source suppliers) that are needed for such manufacturing or sterilization, or provide products to our customers, including events that impact key distributors. In particular, there has been increased regulatory focus on the use and emission of ethylene oxide in sterilization processes, and additional regulatory requirements may be imposed in the future that could adversely impact us or our third-party sterilization providers.
|
|
•
|
IT system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, which could impair our ability or that of our customers, suppliers and other business partners to conduct business, result in the loss of our trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners, or of patients, including sensitive personal data, or result in efficacy or safety concerns for certain of our products, and result in investigations, legal proceedings, liability, expense or reputational damage or actions by regulatory bodies or civil litigation.
|
|
•
|
Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, successfully complete clinical trials, obtain and maintain regulatory approvals, clearances and registrations in the U.S. and abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which could preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from the FDA or other regulatory agencies due to government shutdowns or reductions in government staffing or changes in the regulatory process may also delay product launches and increase development costs.
|
|
•
|
The impact of business combinations or divestitures, including any volatility in earnings relating to acquisition-related costs, and our ability to successfully integrate any business we may acquire.
|
|
•
|
Risks relating to our overall level of indebtedness, including our ability to service our debt and refinance our indebtedness, which is dependent upon the capital markets and the overall macroeconomic environment and our financial condition at such time.
|
|
•
|
The risks associated with the qualification of the spin-off of our former Diabetes Care business, and the spin-off of our former Biosciences and Diagnostic Solutions businesses and subsequent combination with Waters in a Reverse Morris Trust transaction, as tax-free transactions for U.S. federal income tax purposes.
|
|
•
|
Risks associated with our development, deployment and use of AI in our products and business operations.
|
TABLE OF CONTENTS
|
•
|
Our ability to penetrate or expand our operations in emerging markets, which depends on local economic and political conditions, and how well we are able to make necessary infrastructure enhancements to production facilities and distribution networks.
|
|
•
|
Our ability to recruit and retain key employees and the impact of labor conditions which could increase employee turnover or increase our labor and operating costs and negatively affect our ability to efficiently operate our business.
|
|
•
|
Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation, the development of alternative therapies for disease states that may be delivered without a medical device, or otherwise.
|
|
•
|
The impact of climate change, legal, regulatory or market measures to address climate change, such as regulation of greenhouse gas emissions, zero-carbon energy and sustainability mandates and related disclosure requirements, and additional taxes on fuel and energy, or related sustainability efforts, and changing customer and other stakeholder preferences and requirements, such as those regarding the use of materials of concern, shifting demand for products with lower environmental footprints, and for progress toward sustainability goals and greenhouse gas reduction targets.
|
|
•
|
Natural disasters, including the impacts of hurricanes, tornadoes, windstorms, fires, earthquakes and floods and other extreme weather events, public health crises (such as pandemics and epidemics), war, terrorism, labor disruptions and international conflicts that could cause significant economic disruption and political and social instability, resulting in decreased demand for our products, adversely affect our manufacturing and distribution capabilities or cause interruptions in our supply chain, and our response may involve the implementation of measures which may not be successful.
|
|
•
|
Pending and potential future litigation or other proceedings asserting, and/or investigations concerning and/or subpoenas and requests seeking information with respect to, alleged violations of law (including in connection with federal and/or state healthcare programs (such as Medicare or Medicaid), government contracts and/or sales and marketing practices (such as investigative subpoenas and the civil investigative demands received by us)), potential anti-corruption and related internal control violations under the Foreign Corrupt Practices Act, antitrust claims, securities law claims, environmental and product liability matters (including pending claims relating to ethylene oxide, our hernia repair implant products, surgical continence and pelvic organ prolapse products for women, vena cava filter products and implantable ports, which involve, or could involve in the future, lawsuits seeking class action status or seeking to establish multi-district or other consolidated proceedings), data privacy breaches and patent infringement, and the availability or collectability of insurance relating to any such claims.
|
|
•
|
New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including, without limitation, laws relating to sales practices, healthcare, environmental protection and reporting, price controls, privacy, data protection, cybersecurity, AI, employment, labor and licensing and regulatory requirements for new products and products in the post-marketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. New environmental laws, particularly with respect to the emission of greenhouse gases, may also increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to us.
|
|
•
|
The effect of adverse media exposure or other publicity regarding our business or operations, including the effect on our reputation or demand for our products.
|
|
•
|
The effect of market fluctuations on the value of assets in our pension plans and on actuarial interest rate and asset return assumptions, which could require us to make additional contributions to the plans or increase our pension plan expense.
|
|
•
|
Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
|
|
•
|
Our ability to execute our New BD strategy, Excellence Unleashed, as expected.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
the time remaining to the maturity of the notes;
|
|
•
|
the outstanding amount of the notes;
|
TABLE OF CONTENTS
|
•
|
the terms related to redemption of the notes; and
|
|
•
|
the level, direction and volatility of market interest rates generally.
|
|
•
|
Market Interest Rates. The Issuer and BD expect that the market value of the notes will be affected by changes in market interest rates. In general, if market interest rates increase, the market value of the notes may decrease. The Issuer cannot predict the future level of market interest rates.
|
|
•
|
Prevailing currency exchange rates. The Issuer and BD expect that the amount realizable upon a sale of the notes, in U.S. dollars or other non-euro currency, will be affected by currency exchange rates prevailing at the time of sale, as discussed under "-Holders of the notes may be subject to the effects of foreign currency exchange rate fluctuations, as well as possible exchange controls, relating to the euro" below.
|
|
•
|
The Issuer's and BD's Credit Rating, and BD's Financial Condition and Results of Operations. The Issuer and BD expect that the notes will be rated by one or more nationally recognized statistical rating organizations. Any rating agency that rates the notes may lower the Issuer's or BD's rating or decide not to rate the notes in its sole discretion. Actual or anticipated changes in the Issuer's or BD's credit ratings, financial condition or results of operations may affect the market value of the notes. In general, if the Issuer's or BD's credit rating is downgraded, the market value of the notes may decrease. A credit rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time by the assigning rating organization. No person is obligated to maintain any rating on the notes, and, accordingly, neither Issuer nor BD can assure you that the ratings assigned to the notes will not be lowered or withdrawn by the assigning rating organization at any time thereafter. Furthermore, the credit ratings assigned to the notes may not reflect the potential impact of all risks related to trading markets, if any, for, or trading value of, your notes. See "-Ratings of the notes may not reflect all risks of your investment in the notes." Accordingly, you should consult your own financial and legal advisors as to the risks entailed by an investment in the notes and the suitability of investing in the notes in light of your particular circumstances.
|
TABLE OF CONTENTS
|
•
|
significant changes in rates of exchange between the euro and the investor's home currency; and
|
|
•
|
the imposition or modification of foreign exchange controls with respect to the euro or the investor's home currency.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
an actual basis; and
|
|
•
|
an as adjusted basis giving effect to this offering and the use of proceeds therefrom as described under "Use of Proceeds" above.
|
|
|
|
|
|
|||
|
|
|
As of March 31, 2026
|
||||
|
(in millions)
|
|
|
Actual
|
|
|
As
Adjusted(5)
|
|
Cash, cash equivalents and short-term investments
|
|
|
$813
|
|
|
$807
|
|
Short-term indebtedness (excludes current portion)
|
|
|
$1,183
|
|
|
$1,183
|
|
Long-term indebtedness (includes current portion):
|
|
|
|
|
||
|
Revolving Credit Facility(1)
|
|
|
-
|
|
|
-
|
|
1.208% Euro Notes due 2026(2),(3)
|
|
|
695
|
|
|
-
|
|
6.700% Notes due 2026
|
|
|
115
|
|
|
115
|
|
1.900% Euro Notes due 2026(2)
|
|
|
579
|
|
|
579
|
|
3.700% Notes due 2027
|
|
|
1,723
|
|
|
1,723
|
|
7.000% Debentures due 2027
|
|
|
84
|
|
|
84
|
|
4.693% Notes due 2028
|
|
|
798
|
|
|
798
|
|
6.700% Debentures due 2028
|
|
|
86
|
|
|
86
|
|
0.334% Euro Notes due 2028(2),(3)
|
|
|
1,041
|
|
|
1,041
|
|
4.874% Notes due 2029
|
|
|
623
|
|
|
623
|
|
5.081% Notes due 2029
|
|
|
155
|
|
|
155
|
|
3.553% Euro Notes due 2029(2),(3)
|
|
|
924
|
|
|
924
|
|
2.823% Notes due 2030
|
|
|
747
|
|
|
747
|
|
3.519% Euro Notes due 2031(2)
|
|
|
865
|
|
|
865
|
|
1.957% Notes due 2031
|
|
|
995
|
|
|
995
|
|
3.828% Euro Notes due 2032(2)
|
|
|
1,153
|
|
|
1,153
|
|
4.298% Notes due 2032
|
|
|
497
|
|
|
497
|
|
5.110% Notes due 2034
|
|
|
546
|
|
|
546
|
|
1.213% Euro Notes due 2036(2),(3)
|
|
|
692
|
|
|
692
|
|
4.029% Euro Notes due 2036(2),(3)
|
|
|
921
|
|
|
921
|
|
6.000% Notes due 2039
|
|
|
60
|
|
|
60
|
|
5.000% Notes due 2040
|
|
|
54
|
|
|
54
|
|
1.336% Euro Notes due 2041(2),(3)
|
|
|
1,035
|
|
|
1,035
|
|
4.875% Notes due 2044
|
|
|
145
|
|
|
145
|
|
4.685% Notes due 2044
|
|
|
458
|
|
|
458
|
|
4.669% Notes due 2047
|
|
|
812
|
|
|
812
|
|
3.794% Notes due 2050
|
|
|
294
|
|
|
294
|
|
3.855% Euro Notes due 2033 offered hereby(3),(4)
|
|
|
-
|
|
|
701
|
|
Other long-term indebtedness
|
|
|
1
|
|
|
1
|
|
Total long-term indebtedness
|
|
|
16,096
|
|
|
16,102
|
|
Total shareholders' equity
|
|
|
24,133
|
|
|
24,133
|
|
Total capitalization
|
|
|
$41,412
|
|
|
$41,419
|
|
|
|
|
|
|
|
|
|
*
|
Amounts may not add due to rounding.
|
TABLE OF CONTENTS
|
1.
|
As of March 31, 2026, BD's $2.75 billion Revolving Credit Facility was undrawn and BD had access to an additional $500 million of availability subject to lender commitments.
|
|
2.
|
Amount translated using an exchange rate of €1.00 to $1.1589.
|
|
3.
|
Issued by the Issuer, which is an indirect, wholly-owned finance subsidiary of BD. The notes are fully and unconditionally guaranteed on a senior unsecured basis by BD.
|
|
4.
|
Amount translated using the exchange rate of €1.00 to $1.1781 on May 11, 2026, as reported by Bloomberg.
|
|
5.
|
Assumes cash is used to pay the expected accrued and unpaid interest, premiums and fees and expenses related to the bond repayments.
|
TABLE OF CONTENTS
|
•
|
Title of the notes: 3.855% Notes due 2033
|
|
•
|
Issuer of the notes: Becton Dickinson Euro Finance S.à r.l.
|
|
•
|
Guarantor of the notes: Becton, Dickinson and Company
|
|
•
|
Total principal amount being issued: €600,000,000
|
|
•
|
Maturity date: May 20, 2033
|
|
•
|
Interest rate: 3.855% per annum
|
|
•
|
Currency of Payment: See "-Issuance in Euro"
|
|
•
|
Date interest starts accruing: May 20, 2026
|
|
•
|
Annual interest payment date: May 20
|
|
•
|
First annual interest payment date: May 20, 2027
|
|
•
|
Regular record date for interest: The business day (on which each of Euroclear Bank SA/NV and Clearstream Banking S.A. is open for business) preceding the interest payment date of each year
|
|
•
|
Optional Redemption: See "-Optional Redemption"
|
|
•
|
Purchase of Notes Upon a Change of Control Triggering Event: See "-Offer to Repurchase Upon Change of Control Triggering Event"
|
|
•
|
Payment of Additional Amounts: See "-Payment of Additional Amounts"
|
|
•
|
Redemption for Tax Reasons: See "-Redemption for Tax Reasons"
|
|
•
|
Listing: Application has been made to the NYSE for the listing of the notes.
|
|
•
|
Governing Law: The indenture, the notes and the guarantee thereof will be governed by the laws of the State of New York. The provisions of articles 470-1 to 470-19 (inclusive) of the Luxembourg law of 10 August 1915 on commercial companies, as amended, are expressly excluded.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
100% of the principal amount of the notes to be redeemed; and
|
|
•
|
the sum of the present values of the remaining scheduled payments on the notes being redeemed, discounting such payments to the redemption date on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable comparable government bond rate, plus 15 basis points, plus, in each case, accrued and unpaid interest thereon to, but excluding, the redemption date. The Trustee shall have no responsibility for calculating the redemption price.
|
TABLE OF CONTENTS
|
•
|
accept for payment all notes or portions of notes properly tendered pursuant to the Change of Control Offer;
|
|
•
|
deposit with the trustee or a paying agent the required payment for all properly tendered notes or portions of notes not validly withdrawn; and
|
|
•
|
deliver or cause to be delivered to the trustee the notes properly accepted, together with an officer's certificate stating the aggregate principal amount of notes or portions of notes being repurchased.
|
|
•
|
the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the assets of BD and its subsidiaries taken as a whole to any Person (including any "person" (as that term is defined in Section 13(d)(3) of the Exchange Act)) other than to BD or one of its subsidiaries;
|
|
•
|
the consummation of any transaction (including without limitation, any merger or consolidation) the result of which is that any Person (including any "person" (as that term is defined in Section 13(d)(3)
|
TABLE OF CONTENTS
|
•
|
the adoption of a plan relating to the liquidation or dissolution of BD.
|
TABLE OF CONTENTS
|
•
|
to any tax, assessment or other governmental charge that would not have been imposed but for the holder (or the beneficial owner for whose benefit such holder holds such note), or a fiduciary, settlor, beneficiary, member or shareholder of the holder, or a person holding a power over an estate or trust administered by a fiduciary holder, being treated as:
|
|
•
|
being or having been present in, or engaged in a trade or business in, the relevant Taxing Jurisdiction, or having or having had a permanent establishment in such Taxing Jurisdiction;
|
|
•
|
having a current or former connection with the relevant Taxing Jurisdiction (other than a connection arising solely as a result of the ownership of the notes, the receipt of any payment in respect of the notes or the enforcement of any rights under the indenture), including being or having been a citizen of such Taxing Jurisdiction or treated as being or having been a resident thereof;
|
|
•
|
being or having been a personal holding company, a passive foreign investment company or a controlled foreign corporation for United States federal income tax purposes, a foreign tax exempt organization, or a corporation that has accumulated earnings to avoid United States federal income tax;
|
|
•
|
being or having been a "10-percent shareholder," as defined in section 871(h)(3) of the United States Internal Revenue Code of 1986, as amended (the "Code"), or any successor provision, of us or BD; or
|
|
•
|
being a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business, within the meaning of section 881(c)(3) of the Code or any successor provision;
|
|
•
|
to any holder that is not the sole beneficial owner of the notes, or a portion of the notes, or that is a fiduciary, partnership or limited liability company, but only to the extent that a beneficiary or settlor with respect to the fiduciary, or a beneficial owner or member of the partnership or limited liability company would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment;
|
|
•
|
to any tax, assessment or other governmental charge that would not have been imposed but for the failure of the holder or any other person to comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the relevant Taxing Jurisdiction of the holder or beneficial owner of the notes, if compliance is required by statute, by regulation of the relevant Taxing Jurisdiction or any taxing authority therein or by an applicable income tax treaty to which the relevant Taxing Jurisdiction is a party as a precondition to exemption from such tax, assessment or other governmental charge;
|
|
•
|
to any tax, assessment or other governmental charge that is imposed otherwise than by withholding by us or a paying agent from the payment;
|
|
•
|
to any estate, inheritance, gift, sales, excise, transfer, wealth, capital gains or personal property tax or similar tax, assessment or other governmental charge;
|
|
•
|
to any tax, assessment or other governmental charge that would not have been imposed but for the presentation by the holder of any note, where presentation is required, for payment on a date more than 30 days after the date on which payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later;
|
|
•
|
to any tax assessment or other governmental charge required to be withheld or deducted that is imposed on a payment pursuant to sections 1471 through 1474 of the Code (or any amended or successor version of such sections that is substantively comparable and not materially more onerous to comply with), any Treasury Regulations promulgated thereunder, or any other official interpretations thereof
|
TABLE OF CONTENTS
|
•
|
to any tax assessment or other governmental charge that is imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later;
|
|
•
|
to any tax, assessment or other governmental charge that is imposed by reason of the failure of the beneficial owner to fulfill the statement requirements of section 871(h) or section 881(c) of the Code;
|
|
•
|
to any tax imposed pursuant to section 871(h)(6) or section 881(c)(6) of the Code (or any amended or successor provisions);
|
|
•
|
to any tax imposed pursuant to the Luxembourg law dated 23 December 2005 as amended from time to time (the "Relibi Law"); or
|
|
•
|
in the case of any combination of the above bulleted items under this heading "-Payment of Additional Amounts."
|
|
•
|
ISIN: XS3368849348
|
|
•
|
Common Code: 336884934
|
|
•
|
CUSIP Number: L076BM AD8
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
transfers of securities and cash within Euroclear;
|
|
•
|
withdrawal of securities and cash from Euroclear; and
|
|
•
|
receipt of payments with respect to securities in Euroclear.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
the average exchange rate in effect during the interest accrual period, or portion thereof, within such U.S. Holder's taxable year; or
|
|
•
|
at such U.S. Holder's election, at the spot rate of exchange on (1) the last day of the accrual period, or the last day of the taxable year within such accrual period if the accrual period spans more than one taxable year, or (2) the date of receipt, if such date is within five business days of the last day of the accrual period or taxable year.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
(i)
|
is an investor as defined in a specific law (such as the law on family wealth management companies of 11 May 2007, as amended, the law on undertakings for collective investment of 17 December 2010, as amended, the law on specialized investment funds of 13 February 2007, as amended, the law on reserved alternative investment funds of 23 July 2016, the law on securitisation of 22 March 2004, as amended, the law on venture capital vehicles of 15 June 2004, as amended and the law on pension saving companies and associations of 13 July 2005);
|
|
(ii)
|
is, in whole or in part, exempt from tax;
|
|
(iii)
|
acquires, owns or disposes of the notes in connection with a membership of a management board, a supervisory board, an employment relationship, a deemed employment relationship or management role;
|
|
(iv)
|
has a substantial interest in the Issuer or a deemed substantial interest in the Issuer for Luxembourg tax purposes. Generally, a person holds a substantial interest if such person owns or is deemed to own, directly or indirectly, more than 10% of the shares or interest in an entity.
|
TABLE OF CONTENTS
|
(i)
|
no Luxembourg inheritance tax is levied on the transfer of the notes upon the death of a holder in cases where the deceased was not a resident or a deemed resident of Luxembourg for inheritance tax purposes;
|
|
(ii)
|
by way of gift, Luxembourg gift tax will be levied in the event that the gift is made pursuant to a notarial deed signed before a Luxembourg notary or produced for registration, directly or indirectly, before the Registration, Estates and VAT Department (Administration de l'enregistrement, des domaines et de la TVA).
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
|
|
|
|
|
Underwriter
|
|
|
Principal
Amount of Securities
to be Purchased
|
|
Barclays Bank PLC
|
|
|
€123,000,000
|
|
BNP PARIBAS
|
|
|
€123,000,000
|
|
Goldman Sachs & Co. LLC
|
|
|
€123,000,000
|
|
Morgan Stanley & Co. International plc
|
|
|
€123,000,000
|
|
MUFG Securities (Europe) N.V.
|
|
|
€18,000,000
|
|
Scotiabank (Ireland) Designated Activity Company
|
|
|
€18,000,000
|
|
U.S. Bancorp Investments, Inc
|
|
|
€18,000,000
|
|
Academy Securities, Inc
|
|
|
€6,000,000
|
|
Banco Santander, S.A
|
|
|
€6,000,000
|
|
ING Bank N.V., Belgian branch
|
|
|
€6,000,000
|
|
Intesa Sanpaolo IMI Securities Corp
|
|
|
€6,000,000
|
|
Loop Capital Markets LLC
|
|
|
€6,000,000
|
|
Siebert Williams Shank & Co., LLC
|
|
|
€12,000,000
|
|
Standard Chartered Bank
|
|
|
€6,000,000
|
|
TD Global Finance unlimited company
|
|
|
€6,000,000
|
|
|
|
€600,000,000
|
|
|
|
|
|
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
(a)
|
the expression "retail investor" means a person who is one (or more) of the following:
|
|
(i)
|
a retail client as defined in point (11) of Article 4(1) of MiFID II; or
|
|
(ii)
|
a customer within the meaning of the Insurance Distribution Directive, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; and
|
|
(b)
|
the expression "offer" includes the communication in any form and by any means of sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase or subscribe for the notes.
|
TABLE OF CONTENTS
|
1)
|
to "qualified investors," as referred to in Article 100 of Legislative Decree No. 58 of 24 February 1998, as amended (the "Decree No. 58") and defined in Article 34-ter, paragraph 1, let. b) of CONSOB Regulation No. 11971 of 14 May 1999, as amended ("Regulation No. 11971"); or
|
|
2)
|
in any other circumstances where an express exemption from compliance with the offer restrictions applies, as provided under Decree No. 58 or Regulation No. 11971.
|
|
(b)
|
made by investment firms, banks or financial intermediaries permitted to conduct such activities in the Republic of Italy in accordance with Legislative Decree No. 385 of 1 September 1993 as amended, Decree No. 58, CONSOB Regulation No. 20307 of 15 February 2018, as amended and any other applicable laws and regulations;
|
|
(c)
|
in compliance with Article 129 of Legislative Decree No. 385 of 1 September 1993, as amended, pursuant to which the Bank of Italy may request information on the issue or the offer of securities in the Republic of Italy and the implementing guidelines of the Bank of Italy issued on 25 August 2015 (as amended on 10 August 2016); and (c) in compliance with any other applicable notification requirement or limitation which may be imposed by CONSOB or the Bank of Italy.
|
TABLE OF CONTENTS
|
(a)
|
corporation (which is not an Accredited Investor), the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an Accredited Investor, or
|
|
(b)
|
trust (where the trustee is not an Accredited Investor), the sole purpose of which is to hold investments and each beneficiary of which is an Accredited Investor, securities or securities-based derivatives contracts (each as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in such trust shall not be transferred within six months after that corporation or trust has subscribed for or acquired the notes except:
|
|
(1)
|
to an Institutional Investor, an Accredited Investor, a Relevant Person or which arises from an offer referred to in Section 275(1A) of the SFA (in the case of that corporation) or Section 276(4)(c)(ii) of the SFA (in the case of that trust);
|
|
(2)
|
where no consideration is or will be given for the transfer;
|
|
(3)
|
where the transfer is by operation of law, as specified in Section 276(7) of the SFA; or
|
TABLE OF CONTENTS
|
(4)
|
as specified in Regulation 37A of the Securities and Futures (offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.
|
|
(a)
|
who meet the criteria of a "Qualified Investor" as defined in the SCA Board of Directors Decision No. 3 R.M. of 2017 (but excluding subparagraph 1(d) in the "Qualified Investor" definition relating to natural persons);
|
|
(b)
|
upon their request and confirmation that they understand that the notes have not been approved or licensed by or registered with the UAE Central Bank, the SCA, DFSA or any other relevant licensing authorities or governmental agencies in the UAE; and
|
|
(c)
|
upon their confirmation that they understand that the prospectus supplement and the accompanying prospectus must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose.
|
TABLE OF CONTENTS
|
(a)
|
the expression "retail investor" means a person who is: not a professional client as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; and
|
|
(i)
|
the expression "offer" includes the communication in any form and by any means of sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to buy or subscribe for the notes.
|
|
(a)
|
it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of the notes in circumstances in which Section 21(1) of the FSMA does not apply to Becton, Dickinson; and
|
|
(b)
|
it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the notes in, from or otherwise involving the UK.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
Page
|
|
|
BECTON, DICKINSON AND COMPANY
|
|
|
1
|
|
BECTON DICKINSON EURO FINANCE S.À R.L.
|
|
|
1
|
|
WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION BY REFERENCE
|
|
|
2
|
|
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
|
|
|
3
|
|
RISK FACTORS
|
|
|
4
|
|
USE OF PROCEEDS
|
|
|
4
|
|
DESCRIPTION OF SECURITIES
|
|
|
4
|
|
DESCRIPTION OF CAPITAL STOCK OF BECTON, DICKINSON AND COMPANY
|
|
|
5
|
|
DESCRIPTION OF DEPOSITARY SHARES OF BECTON, DICKINSON AND COMPANY
|
|
|
8
|
|
DESCRIPTION OF DEBT SECURITIES OF BECTON, DICKINSON AND COMPANY
|
|
|
9
|
|
DESCRIPTION OF WARRANTS OF BECTON, DICKINSON AND COMPANY
|
|
|
15
|
|
DESCRIPTION OF PURCHASE CONTRACTS OF BECTON, DICKINSON AND COMPANY
|
|
|
16
|
|
DESCRIPTION OF UNITS OF BECTON, DICKINSON AND COMPANY
|
|
|
17
|
|
DESCRIPTION OF DEBT SECURITIES OF BECTON DICKINSON EURO FINANCE S.À R.L.
|
|
|
18
|
|
FORMS OF SECURITIES
|
|
|
26
|
|
PLAN OF DISTRIBUTION
|
|
|
28
|
|
VALIDITY OF SECURITIES
|
|
|
30
|
|
EXPERTS
|
|
|
30
|
|
|
|
|
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
(a)
|
BD's Annual Report on Form 10-K for the fiscal year ended September 30, 2025;
|
|
(b)
|
BD's Current Reports on Form 8-K filed with the SEC on October 15, 2025 (only with respect to Item 5.02 thereto) and November 17, 2025, in each case other than information furnished under Item 2.02 or 7.01 of Form 8-K; and
|
|
(c)
|
the description of BD's common stock, par value $1.00 per share, contained in its registration statement on Form 8-A filed with the SEC, including any further amendment or report filed for the purpose of updating such description.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
the series, the number of shares offered and the liquidation value of the preferred stock;
|
|
•
|
the price at which the preferred stock will be issued;
|
|
•
|
the dividend rate, the dates on which the dividends will be payable and other terms relating to the payment of dividends on the preferred stock;
|
|
•
|
the voting rights of the preferred stock;
|
|
•
|
whether the preferred stock is redeemable or subject to a sinking fund, and the terms of any such redemption or sinking fund;
|
|
•
|
whether the preferred stock is convertible or exchangeable for any other securities, and the terms of any such conversion; and
|
|
•
|
any additional rights, preferences, qualifications, limitations and restrictions of the preferred stock.
|
|
•
|
an authorization for the issuance of blank check preferred stock. Our board of directors can set the voting rights, redemption rights, conversion rights and other rights relating to such preferred stock and could issue such stock in either private or public transactions. In some circumstances, the blank check preferred stock could be issued and have the effect of preventing a merger, tender offer or other takeover attempt that the board of directors opposes;
|
|
•
|
providing advanced written notice procedures and limitations with respect to shareholder proposals and the nomination of candidates for election as directors other than nominations made by or at the direction of our board of directors;
|
|
•
|
providing a statement that special meetings of our shareholders may only be called by the Chairman of our board of directors, the Chief Executive Officer or our board of directors, or on request in writing of shareholders of record owning 15% or more of the voting power of our outstanding capital stock entitled to vote (limited to shares owned, directly or indirectly, by any shareholder that constitutes such person's net long position), and providing that a special meeting will not be held if (a) the meeting request is delivered during the period commencing 90 days prior to the first anniversary of the date of the
|
TABLE OF CONTENTS
|
•
|
allowing our directors to fill vacancies on our board of directors, including vacancies resulting from removal or enlargement of our board of directors;
|
|
•
|
granting our board of directors the authority to amend and repeal our by-laws without a stockholder vote; and
|
|
•
|
permitting a majority of our board of directors to fix the number of directors. These provisions may have the effect of delaying, deferring or preventing a change in control.
|
|
•
|
the merger or consolidation of the corporation with the interested stockholder or any corporation that is or after the merger or consolidation would be an affiliate or associate of the interested stockholder,
|
|
•
|
the sale, lease, exchange, mortgage, pledge, transfer or other disposition to an interested stockholder or any affiliate or associate of the interested stockholder of 10% or more of the corporation's assets, or
|
|
•
|
the issuance or transfer to an interested stockholder or any affiliate or associate of the interested stockholder of 5% or more of the aggregate market value of the stock of the corporation.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
the designation of the debt securities of the series;
|
|
•
|
any limit upon the aggregate principal amount of the debt securities of the series and any limitation on our ability to increase the aggregate principal amount of debt securities of that series after initial issuance;
|
|
•
|
any date on which the principal of the debt securities of the series is payable (which date may be fixed or extendible);
|
|
•
|
the interest rate or rates and the method for calculating the interest rate;
|
|
•
|
if other than as provided in the indenture, any place where principal of and interest on debt securities of the series will be payable, where debt securities of the series may be surrendered for exchange, where notices or demands may be served and where notice to holders may be published and any time of payment at any place of payment;
|
|
•
|
whether we have a right to redeem debt securities of the series and any terms thereof;
|
|
•
|
whether you have a right to require us to redeem, repurchase or repay debt securities of the series and any terms thereof;
|
|
•
|
if other than denominations of $1,000 and any integral multiple, the denominations in which debt securities of the series shall be issuable;
|
|
•
|
if other than the principal amount, the portion of the principal amount of debt securities of the series which will be payable upon declaration of acceleration of the maturity;
|
|
•
|
if other than U.S. dollars, the currency or currencies in which payment of the principal of and interest on the debt securities of the series will be payable;
|
|
•
|
whether the principal and any premium or interest is payable in a currency other than the currency in which the debt securities are denominated;
|
|
•
|
whether we have an obligation to pay additional amounts on the debt securities of the series in respect of any tax, assessment or governmental charge withheld or deducted and any right that we may have to redeem those debt securities rather than pay the additional amounts;
|
|
•
|
if other than the person acting as trustee, any agent acting with respect to the debt securities of the series;
|
|
•
|
any provisions for the defeasance of any debt securities of the series in addition to, in substitution for or in modification of the provisions described in "- Defeasance and Covenant Defeasance";
|
TABLE OF CONTENTS
|
•
|
the identity of any depositary for registered global securities of the series other than The Depository Trust Company and any circumstances other than those described in "- Registered global securities" in which any person may have the right to obtain debt securities in definitive form in exchange;
|
|
•
|
any events of default applicable to any debt securities of the series in addition to, in substitution for or in modification of those described in "- Events of Default";
|
|
•
|
any covenants applicable to any debt securities of the series in addition to, in substitution for or in modification of those described in "- Covenants"; and
|
|
•
|
any other terms of the debt securities of the series.
|
|
•
|
we are the surviving person; or
|
|
•
|
the surviving person is a corporation organized and validly existing under the laws of the United States of America or any U.S. State or the District of Columbia and expressly assumes by a supplemental indenture all of our obligations under the debt securities and under the indenture; and
|
|
•
|
immediately before and after the transaction or each series of transactions, no default or event of default shall have occurred and be continuing; and
|
|
•
|
certain other conditions are met.
|
|
•
|
default in the payment of interest on any debt security when due, which continues for 30 days;
|
|
•
|
default in the payment of principal of any debt security when due;
|
|
•
|
default in the deposit of any sinking fund payment when due;
|
|
•
|
default in the performance of any other obligation contained in the indenture, which default continues for 60 days after we receive written notice of it from the trustee or from the holders of 25% in principal amount of the outstanding debt securities of that series;
|
|
•
|
specified events of bankruptcy, insolvency or reorganization of our company for the benefit of our creditors; or
|
TABLE OF CONTENTS
|
•
|
any other event of default established for the debt securities of that series.
|
|
•
|
the entire principal of the debt securities of that series; or
|
|
•
|
if the debt securities are original issue discount securities, that portion of the principal as may be described in the applicable prospectus supplement.
|
|
•
|
in the payment of the principal of, or interest on, any debt security of that series; or
|
|
•
|
in respect of a covenant or provision of such indenture which cannot under the terms of the indenture be amended or modified without the consent of the holder of each outstanding debt security that is adversely affected thereby.
|
TABLE OF CONTENTS
|
•
|
mortgages existing on properties on the date of the indenture,
|
|
•
|
mortgages on properties, shares of stock or debt existing at the time of acquisition (including acquisition through merger or consolidation), purchase money mortgages and construction mortgages,
|
|
•
|
mortgages on property of, or on any shares of stock or debt of, any corporation existing at the time that corporation becomes a Restricted Subsidiary,
|
|
•
|
mortgages in favor of Federal and State governmental bodies to secure progress, advance or other payments pursuant to any contract or provision of any statute,
|
|
•
|
mortgages in favor of us or a Restricted Subsidiary,
|
|
•
|
mortgages in connection with the issuance of tax-exempt industrial development bonds,
|
|
•
|
mortgages under workers' compensation laws, unemployment insurance laws or similar legislation, or deposit bonds to secure statutory obligations (or pledges or deposits for similar purposes in the ordinary course of business), or liens imposed by law and certain other liens or other encumbrances, and
|
|
•
|
subject to certain limitations, any extension, renewal or replacement of any mortgage referred to in the foregoing clauses.
|
|
•
|
the commitment to enter into the sale and leaseback transaction was obtained during that 120-day period;
|
|
•
|
we or our Restricted Subsidiaries could create debt secured by a mortgage on the Principal Property as described under "- Restrictions on Secured Debt" above in an amount equal to the Attributable Debt with respect to the sale and leaseback transaction without equally and ratably securing the debt securities;
|
TABLE OF CONTENTS
|
•
|
within 120 days after the sale or transfer, we designate an amount to the retirement of Funded Debt, subject to credits for voluntary retirements of Funded Debt, equal to the greater of
|
|
(i)
|
the net proceeds of the sale of the Principal Property and
|
|
(ii)
|
the fair market value of the Principal Property, or
|
|
•
|
we or any Restricted Subsidiary, within a period commencing 180 days prior to and ending 180 days after the sale or transfer, have expended or reasonably expect to expend within such period any monies to acquire or construct any Principal Property or properties in which event we or that Restricted Subsidiary enter into the sale and leaseback transaction, but (unless certain other conditions are met) only to the extent that the Attributable Debt with respect to the sale and leaseback transaction is less than the monies expended or to be expended.
|
|
•
|
evidence the succession of another corporation to our company and the assumption of our covenants by that successor,
|
|
•
|
provide for a successor trustee with respect to the debt securities of all or any series,
|
|
•
|
establish the forms and terms of the debt securities of any series,
|
|
•
|
provide for uncertificated or unregistered debt securities, or
|
|
•
|
cure any ambiguity or correct any mistake or to make any change that does not materially adversely affect the legal rights of any holder of the debt securities under the indenture.
|
|
•
|
change the stated maturity date of any installment of principal of, or interest on, any debt security,
|
|
•
|
reduce the principal amount of, or the rate of interest on, any debt security,
|
|
•
|
adversely affect the rights of any debt security holder under any mandatory redemption or repurchase provision,
|
|
•
|
reduce the amount of principal of an original issue discount security payable upon acceleration of its maturity,
|
|
•
|
change the place or currency of payment of principal of, or any premium or interest on, any debt security,
|
|
•
|
impair the right to institute suit for the enforcement of any payment or delivery on or with respect to any debt security,
|
|
•
|
reduce the percentage in principal amount of debt securities of any series, the consent of whose holders is required to modify or amend the indenture or to waive compliance with certain provisions of the indenture,
|
|
•
|
reduce the percentage in principal amount of debt securities of any series, the consent of whose holders is required to waive any past default,
|
|
•
|
waive a default in the payment of principal of, or interest on, any debt security,
|
|
•
|
change any of our obligations to maintain offices or agencies where the debt securities may be surrendered for payment, registration or transfer and where notices and demands may be served upon us, or
|
|
•
|
change any of the above provisions, except to increase any such percentage or to provide that certain other provisions of the indenture cannot be modified or waived without the consent of each holder of any debt security affected.
|
TABLE OF CONTENTS
|
•
|
to defease and be discharged from any and all obligations with respect to
|
|
•
|
debt securities of any series payable within one year, or
|
|
•
|
other debt securities of any series upon the conditions described below; or
|
|
•
|
to be released from our obligations with respect to covenants described under "-Covenants" above and, if specified in the applicable prospectus supplement, other covenants applicable to the debt securities of any series ("covenant defeasance"),
|
TABLE OF CONTENTS
|
•
|
the specific designation and aggregate number of, and the price at which we will issue, the warrants;
|
|
•
|
the currency or currency units in which the offering price, if any, and the exercise price are payable;
|
|
•
|
the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants;
|
|
•
|
whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit;
|
|
•
|
any applicable material U.S. federal income tax consequences;
|
|
•
|
the identity of the warrant agent for the warrants and of any other depositories, execution or paying agents, transfer agents, registrars or other agents;
|
|
•
|
the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange;
|
|
•
|
whether the warrants are to be sold separately or with other securities as parts of units;
|
|
•
|
if applicable, the designation and terms of the debt securities, preferred stock or common stock with which the warrants are issued and the number of warrants issued with each security;
|
|
•
|
if applicable, the date from and after which the warrants and the related debt securities, preferred stock or common stock will be separately transferable;
|
|
•
|
the designation, aggregate principal amount, currency and terms of the debt securities that may be purchased upon exercise of the warrants;
|
|
•
|
the number of shares of common stock or preferred stock purchasable upon exercise of a warrant and the price at which those shares may be purchased;
|
|
•
|
if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
|
|
•
|
information with respect to book-entry procedures, if any;
|
|
•
|
any anti-dilution provisions of the warrants;
|
|
•
|
any redemption or call provisions; and
|
|
•
|
any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.
|
TABLE OF CONTENTS
|
•
|
debt securities or equity securities issued by us or securities of third parties, a basket of such securities, an index or indices of such securities or any combination as specified in the applicable prospectus supplement;
|
|
•
|
currencies; or
|
|
•
|
commodities.
|
TABLE OF CONTENTS
|
•
|
the terms of the units and of the purchase contracts, warrants, debt securities, preferred stock and common stock comprising the units, including whether and under what circumstances the securities comprising the units may be traded separately;
|
|
•
|
a description of the terms of any unit agreement governing the units; and
|
|
•
|
a description of the provisions for the payment, settlement, transfer or exchange of the units.
|
TABLE OF CONTENTS
|
•
|
the designation of the debt securities of the series;
|
|
•
|
any limit upon the aggregate principal amount of the debt securities of the series and any limitation on our ability to increase the aggregate principal amount of debt securities of that series after initial issuance;
|
|
•
|
any date on which the principal of the debt securities of the series is payable (which date may be fixed or extendible);
|
|
•
|
the interest rate or rates and the method for calculating the interest rate;
|
|
•
|
if other than as provided in the Finance Indenture, any place where principal of and interest on debt securities of the series will be payable, where debt securities of the series may be surrendered for exchange, where notices or demands may be served and where notice to holders may be published and any time of payment at any place of payment;
|
|
•
|
whether Becton Finance has a right to redeem debt securities of the series and any terms thereof;
|
|
•
|
whether you have a right to require Becton Finance to redeem, repurchase or repay debt securities of the series and any terms thereof;
|
|
•
|
if other than denominations of $1,000 and any integral multiple, the denominations in which debt securities of the series shall be issuable;
|
|
•
|
if other than the principal amount, the portion of the principal amount of debt securities of the series which will be payable upon declaration of acceleration of the maturity;
|
|
•
|
if other than U.S. dollars, the currency or currencies in which payment of the principal of and interest on the debt securities of the series will be payable;
|
TABLE OF CONTENTS
|
•
|
whether the principal and any premium or interest is payable in a currency other than the currency in which the debt securities are denominated;
|
|
•
|
whether Becton Finance has an obligation to pay additional amounts on the debt securities of the series in respect of any tax, assessment or governmental charge withheld or deducted and any right that Becton Finance may have to redeem those debt securities rather than pay the additional amounts;
|
|
•
|
if other than the person acting as trustee, any agent acting with respect to the debt securities of the series;
|
|
•
|
any provisions for the defeasance of any debt securities of the series in addition to, in substitution for or in modification of the provisions described in "- Defeasance and Covenant Defeasance";
|
|
•
|
the identity of any depositary for registered global securities of the series other than The Depository Trust Company and any circumstances other than those described in "- Registered global securities" in which any person may have the right to obtain debt securities in definitive form in exchange;
|
|
•
|
any events of default applicable to any debt securities of the series in addition to, in substitution for or in modification of those described in "- Events of Default";
|
|
•
|
any covenants applicable to any debt securities of the series in addition to, in substitution for or in modification of those described in "- Covenants";
|
|
•
|
the terms of the guarantees by the Guarantor, including any corresponding changes to the provisions of the Finance Indenture; and
|
|
•
|
any other terms of the debt securities of the series.
|
|
•
|
the surviving person is Becton Finance or the Guarantor; or
|
|
•
|
the surviving person is a corporation, partnership, limited liability company, an association, trust or other entity organized and validly existing under the laws of the United States of America, any U.S. State or the District of Columbia, any member state of the European Union, Ireland, Canada, United Kingdom, Bermuda, the Cayman Islands, Singapore, Hong Kong, Switzerland or the United Arab Emirates and expressly assumes by a supplemental indenture all of the obligations of Becton Finance under the debt securities and under the Finance Indenture; and
|
|
•
|
immediately after the transaction or each series of transactions, no default or event of default shall have occurred and be continuing; and
|
|
•
|
certain other conditions are met.
|
TABLE OF CONTENTS
|
•
|
the Guarantor is the surviving person; or
|
|
•
|
the surviving person is a corporation, partnership, limited liability company, an association, trust or other entity organized and validly existing under the laws of the United States of America, any U.S. State or the District of Columbia, any member state of the European Union, Ireland, Canada, United Kingdom, Singapore, Hong Kong or Switzerland and expressly assumes by a supplemental indenture all of the obligations of the Guarantor under the debt securities and under the Finance Indenture; and
|
|
•
|
immediately after the transaction or each series of transactions, no default or event of default shall have occurred and be continuing; and
|
|
•
|
certain other conditions are met.
|
|
•
|
default in the payment of interest on any debt security when due, which continues for 30 days;
|
|
•
|
default in the payment of principal of any debt security when due;
|
|
•
|
default in the deposit of any sinking fund payment when due;
|
|
•
|
default in the performance of any other of Becton Finance's or the Guarantor's obligations contained in the Finance Indenture, which default continues for 60 days after Becton Finance receives written notice of it from the trustee or from the holders of 25% in principal amount of the outstanding debt securities of that series;
|
|
•
|
specified events of bankruptcy, insolvency or reorganization of Becton Finance or the Guarantor for the benefit of their respective creditors;
|
|
•
|
a guarantee of the Guarantor ceases to be in full force and effect or is declared to be null and void and unenforceable or such guarantee is found to be invalid or the Guarantor denies its liability under such guarantee (other than by reason of release of the Guarantor in accordance with the terms of the Finance Indenture); or
|
|
•
|
any other event of default established for the debt securities of that series.
|
|
•
|
the entire principal of the debt securities of that series; or
|
|
•
|
if the debt securities are original issue discount securities, that portion of the principal as may be described in the applicable prospectus supplement.
|
TABLE OF CONTENTS
|
•
|
in the payment of the principal of, or interest on, any debt security of that series; or
|
|
•
|
in respect of a covenant or provision of such Finance Indenture which cannot under the terms of the Finance Indenture be amended or modified without the consent of the holder of each outstanding debt security that is adversely affected thereby.
|
TABLE OF CONTENTS
|
•
|
mortgages existing on properties on the date of the Finance Indenture;
|
|
•
|
mortgages on properties, shares of stock or debt existing at the time of acquisition (including acquisition through merger or consolidation), purchase money mortgages and construction mortgages;
|
|
•
|
mortgages on property of, or on any shares of stock or debt of, any corporation existing at the time that corporation becomes a Restricted Subsidiary;
|
|
•
|
mortgages in favor of Federal and State governmental bodies to secure progress, advance or other payments pursuant to any contract or provision of any statute;
|
|
•
|
mortgages in favor of the Guarantor, Becton Finance or any Restricted Subsidiary;
|
|
•
|
mortgages in connection with the issuance of tax-exempt industrial development bonds;
|
TABLE OF CONTENTS
|
•
|
mortgages under workers' compensation laws, unemployment insurance laws or similar legislation, or deposit bonds to secure statutory obligations (or pledges or deposits for similar purposes in the ordinary course of business), or liens imposed by law and certain other liens or other encumbrances; and
|
|
•
|
subject to certain limitations, any extension, renewal or replacement of any mortgage referred to in the foregoing clauses.
|
|
•
|
the commitment to enter into the sale and leaseback transaction was obtained during that 120-day period;
|
|
•
|
the Guarantor or any Restricted Subsidiary could create debt secured by a mortgage on the Principal Property as described under "- Restrictions on Secured Debt" above in an amount equal to the Attributable Debt with respect to the sale and leaseback transaction without equally and ratably securing the debt securities;
|
|
•
|
within 120 days after the sale or transfer, the Guarantor designates an amount to the retirement of Funded Debt, subject to credits for voluntary retirements of Funded Debt, equal to the greater of:
|
|
(i)
|
the net proceeds of the sale of the Principal Property and
|
|
(ii)
|
the fair market value of the Principal Property, or
|
|
•
|
the Guarantor or any Restricted Subsidiary, within a period commencing 180 days prior to and ending 180 days after the sale or transfer, has expended or reasonably expect to expend within such period any monies to acquire or construct any Principal Property or properties in which event the Guarantor or that Restricted Subsidiary enter into the sale and leaseback transaction, but (unless certain other conditions are met) only to the extent that the Attributable Debt with respect to the sale and leaseback transaction is less than the monies expended or to be expended.
|
|
•
|
evidence the succession of another corporation to Becton Finance or the Guarantor and the assumption of such party's covenants by that successor;
|
|
•
|
provide for a successor trustee with respect to the debt securities of all or any series;
|
|
•
|
establish the forms and terms of the debt securities of any series;
|
|
•
|
provide for uncertificated or unregistered debt securities; or
|
|
•
|
cure any ambiguity or correct any mistake or to make any change that does not materially adversely affect the legal rights of any holder of the debt securities under the Finance Indenture.
|
TABLE OF CONTENTS
|
•
|
change the stated maturity date of any installment of principal of, or interest on, any debt security;
|
|
•
|
reduce the principal amount of, or the rate of interest on, any debt security;
|
|
•
|
adversely affect the rights of any debt security holder under any mandatory redemption or repurchase provision;
|
|
•
|
reduce the amount of principal of an original issue discount security payable upon acceleration of its maturity;
|
|
•
|
change the place or currency of payment of principal of, or any premium or interest on, any debt security;
|
|
•
|
impair the right to institute suit for the enforcement of any payment or delivery on or with respect to any debt security;
|
|
•
|
reduce the percentage in principal amount of debt securities of any series, the consent of whose holders is required to modify or amend the Finance Indenture or to waive compliance with certain provisions of the Finance Indenture;
|
|
•
|
reduce the percentage in principal amount of debt securities of any series, the consent of whose holders is required to waive any past default;
|
|
•
|
waive a default in the payment of principal of, or interest on, any debt security;
|
|
•
|
change any of the obligations of Becton Finance to maintain offices or agencies where the debt securities may be surrendered for payment, registration or transfer and where notices and demands may be served upon Becton Finance;
|
|
•
|
release the Guarantor from its obligations in respect of the guarantee of any series of debt securities or modify the Guarantor's obligations thereunder other than in accordance with the provisions of the Finance Indenture; or
|
|
•
|
change any of the above provisions, except to increase any such percentage or to provide that certain other provisions of the Finance Indenture cannot be modified or waived without the consent of each holder of any debt security affected.
|
|
•
|
to defease and be discharged from any and all obligations with respect to:
|
|
•
|
debt securities of any series payable within one year, or
|
|
•
|
other debt securities of any series upon the conditions described below; or
|
|
•
|
to release any obligations with respect to covenants described under "- Covenants" above and, if specified in the applicable prospectus supplement, other covenants applicable to the debt securities of any series ("covenant defeasance"),
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
Ownership of beneficial interests in a global security will be limited to participants or persons that may hold interests through participants.
|
|
•
|
Ownership of beneficial interests by participants in a global security will be shown on, and the transfer of the beneficial interests will be effected only through, records maintained by the depositary or by its nominee.
|
|
•
|
Ownership of beneficial interests in a global security by persons that hold through participants will be shown on, and the transfer of those beneficial interests will be effected only through, records maintained by the participants.
|
|
•
|
be entitled to have their debt securities represented by the global security registered in their names;
|
|
•
|
receive or be entitled to receive physical delivery of debt securities in certificated form; or
|
|
•
|
be considered the holders for any purposes under the indenture.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
through underwriters or dealers;
|
|
•
|
directly to one or more purchasers;
|
|
•
|
through agents; or
|
|
•
|
through any combination of these methods.
|
|
•
|
the name or names of any underwriters, dealers or agents;
|
|
•
|
the purchase price of such securities and the proceeds to be received by the issuer;
|
|
•
|
any underwriting discounts or agency fees and other items constituting underwriters' or agents' compensation;
|
|
•
|
any initial public offering price;
|
|
•
|
any discounts or concessions allowed or reallowed or paid to dealers; and
|
|
•
|
any securities exchanges on which the securities may be listed.
|
|
•
|
negotiated transactions;
|
|
•
|
at a fixed public offering price or prices, which may be changed;
|
|
•
|
at market prices prevailing at the time of sale;
|
|
•
|
at prices related to prevailing market prices; or
|
|
•
|
at negotiated prices.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
Barclays
|
|
|
BNP PARIBAS
|
|
|
Goldman Sachs & Co. LLC
|
|
|
Morgan Stanley
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MUFG
|
|
|
Scotiabank
|
|
|
US Bancorp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Academy Securities
|
|
|
Santander
|
|
|
ING
|
|
|
IMI - Intesa Sanpaolo
|
|
|
|
|
|
|
|
||||
|
Loop Capital Markets
|
|
|
Siebert Williams Shank
|
|
|
Standard Chartered Bank
|
|
|
TD Securities
|
|
|
|
|
|
|
|
|
|
|
|